Cash Flow Statement

Altimmune (ALT) Revenue (2010 - 2025)

Altimmune (ALT) reported Revenue of $26000.0 for Q4 2025, up 420.0% year-over-year from $5000.0 in Q4 2024, and up 420.0% on a QoQ basis from $5000.0 in Q3 2025.

Altimmune (ALT) has 16 years of Revenue data on file, last reported at $26000.0 in Q4 2025.

  • Quarterly Revenue rose 420.0% year-over-year to $26000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $41000.0 (up 105.0% YoY) and the FY2025 annual result came in at $41000.0, up 105.0% from the prior year.
  • Revenue rose to $26000.0 in Q4 2025 per ALT's latest filing, from $5000.0 in the prior quarter.
  • Across five years, Revenue topped out at $3.3 million in Q4 2021 and bottomed at $2000.0 in Q3 2022.
  • The 5-year median for Revenue is $14500.0 (2022), against an average of $248250.0.
  • The widest annual swing landed in 2022, when Revenue sank 99.21%; it then surged 18000.0% in 2023.
  • Tracing ALT's Revenue over 5 years: stood at $3.3 million in 2021, then slumped by 99.21% to $26000.0 in 2022, then surged by 42.31% to $37000.0 in 2023, then tumbled by 86.49% to $5000.0 in 2024, then soared by 420.0% to $26000.0 in 2025.
  • Per Business Quant, the three latest ALT Revenue figures stand at $26000.0 (Q4 2025), $5000.0 (Q3 2025), and $5000.0 (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.17 Bn
10 Altimmune 379.61 Mn 379.61 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 26,000.00
Sep 30, 2025 5,000.00
Jun 30, 2025 5,000.00
Mar 31, 2025 5,000.00
Dec 31, 2024 5,000.00
Sep 30, 2024 5,000.00
Jun 30, 2024 5,000.00
Mar 31, 2024 5,000.00
Dec 31, 2023 37,000.00
Sep 30, 2023 362,000.00
Jun 30, 2023 6,000.00
Mar 31, 2023 21,000.00
Dec 31, 2022 26,000.00
Sep 30, 2022 2,000.00
Jun 30, 2022 8,000.00
Mar 31, 2022 32,000.00
Dec 31, 2021 3.28 Mn
Sep 30, 2021 158,000.00
Jun 30, 2021 137,000.00
Mar 31, 2021 838,000.00
Dec 31, 2020 2.31 Mn
Sep 30, 2020 2.94 Mn
Jun 30, 2020 4.70 Mn
Mar 31, 2020 2.21 Mn
Dec 31, 2019 575,801.00
Sep 30, 2019 643,978.00
Jun 30, 2019 1.63 Mn
Mar 31, 2019 2.96 Mn
Dec 31, 2018 2.59 Mn
Sep 30, 2018 2.63 Mn
Jun 30, 2018 2.42 Mn
Mar 31, 2018 2.69 Mn
Dec 31, 2017 1.77 Mn
Sep 30, 2017 4.59 Mn
Jun 30, 2017 3.04 Mn
Mar 31, 2017 299,571.00
Dec 31, 2016 1.12 Mn
Sep 30, 2016 4,938.00
Jun 30, 2016 587,502.00
Mar 31, 2016 1.01 Mn
Dec 31, 2015 1.27 Mn
Sep 30, 2015 1.16 Mn
Jun 30, 2015 1.15 Mn
Mar 31, 2015 7.07 Mn
Dec 31, 2014 1.83 Mn
Sep 30, 2014 962,451.00
Jun 30, 2014 3.66 Mn
Mar 31, 2014 3.74 Mn
Dec 31, 2013 3.65 Mn
Sep 30, 2013 3.49 Mn
Jun 30, 2013 4.30 Mn
Mar 31, 2013 6.48 Mn
Dec 31, 2012 6.01 Mn
Sep 30, 2012 6.70 Mn
Jun 30, 2012 6.32 Mn
Mar 31, 2012 6.15 Mn
Dec 31, 2011 6.24 Mn
Sep 30, 2011 5.26 Mn
Jun 30, 2011 6.43 Mn
Mar 31, 2011 6.34 Mn
Dec 31, 2010 6.85 Mn
Sep 30, 2010 6.24 Mn
Jun 30, 2010 4.78 Mn